Dario Eklund, Santhera CEO (file photo)

San­thera kicks idebenone DMD pro­gram to the curb af­ter PhI­II tri­al fails in­ter­im analy­sis

An oft-trou­bled pro­gram at San­thera Phar­ma­ceu­ti­cals {SWX: $SANN} is head­ed for the chop­ping block.

The Swiss biotech an­nounced Tues­day morn­ing that it is dis­con­tin­u­ing a Phase III study for idebenone in pa­tients with Duchenne mus­cu­lar dy­s­tro­phy and re­ceiv­ing steroid treat­ment. In a re­lease, San­thera said that the tri­al failed an in­ter­im analy­sis, and as a re­sult will pull its EMA ap­pli­ca­tion and end glob­al de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.